Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
NCT06282458
Active Not Recruiting
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
Gender:
ALL
Ages:
Between 60 years and 100 years
Trial Updated:
08/08/2024
Locations: Pinnacle Trials, Anniston, Alabama +13 locations
Conditions: Muscle Loss, Obesity
Register for Updates
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
NCT03574597
Completed
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. The participant's chance of getting semaglutide or placebo is the same. The participant will get the study medicine in a pen. The participants will need to use... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
08/06/2024
Locations: Central Alabama Research, Birmingham, Alabama +832 locations
Conditions: Overweight, Obesity
Register for Updates
Mechanisms of Semaglutide Therapy in Heart Failure Patients
NCT06541509
Recruiting
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells. Their stimulation increases insulin and somatostatin secretion, and decreases glucagon secretion. In addition, GLP-1 receptor agonists appear to have multiple extrapancreatic actions, which remain poorly defined. In large clinical trials, semaglutide improved the outcomes in obese patients, patie... Read More
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
08/05/2024
Locations: Greenstone Biosciences, Palo Alto, California +2 locations
Conditions: Heart Failure, Obesity
Register for Updates
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
NCT05819853
Recruiting
Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.
Gender:
FEMALE
Ages:
Between 12 years and 35 years
Trial Updated:
07/29/2024
Locations: University of Colorado Anschutz/Children's Hospital Colorado Aurora, Aurora, Colorado
Conditions: PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
Register for Updates
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
NCT05424003
Recruiting
In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/26/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: NAFLD
Register for Updates
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
NCT05579977
Terminated
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Ry... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/09/2024
Locations: Trinity Clinical Research, Centreville, Alabama +89 locations
Conditions: Diabetes Mellitus, Obesity
Register for Updates
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
NCT05035095
Completed
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants body weight. Participants will either get semaglutide tablets (new medicine) or placebo tablets ('dummy' medicine that looks like semaglutide but has no effect on the body). For a fair comparison, people are divided into two groups at random by a computer. This process is called randomisation. Sem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/05/2024
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +50 locations
Conditions: Obesity, Overweight
Register for Updates
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
NCT04982575
Completed
This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone. Before a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective. Participants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: Uni of Alabama at Birmingham, Birmingham, Alabama +17 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Pharmacogenetics of Response to GLP1R Agonists
NCT05071898
Recruiting
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims: 1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated fir... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
06/20/2024
Locations: Amish Research Clinic, Lancaster, Pennsylvania
Conditions: Obesity, Diabetes Type 2
Register for Updates
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
NCT03596450
Completed
The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the p... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/07/2024
Locations: American Clinical Trials, Buena Park, California +121 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
NCT05822609
Recruiting
The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Diabetic Kidney Disease, Type 1 Diabetes
Register for Updates
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
NCT05780905
Recruiting
A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication. Given th... Read More
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
06/04/2024
Locations: University of Washington - Harborview Medical Center, Seattle, Washington
Conditions: Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
Register for Updates